Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 12, 2015

Primary Completion Date

July 5, 2016

Study Completion Date

September 6, 2017

Conditions
Aplastic Anemia
Interventions
DRUG

Eltrombopag

Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).

DRUG

Rabbit ATG

Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.

DRUG

CsA

CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.

Trial Locations (11)

453-8511

Novartis Investigative Site, Aichi

460-0001

Novartis Investigative Site, Aichi

305-8576

Novartis Investigative Site, Ibaraki

920-8641

Novartis Investigative Site, Ishikawa

981-1293

Novartis Investigative Site, Miyagi

700-0962

Novartis Investigative Site, Okayama

530-0012

Novartis Investigative Site, Osaka

543-8555

Novartis Investigative Site, Osaka

565-0871

Novartis Investigative Site, Osaka

329-0498

Novartis Investigative Site, Tochigi

141-8625

Novartis Investigative Site, Tokyo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY